<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1919">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04319731</url>
  </required_header>
  <id_info>
    <org_study_id>131618</org_study_id>
    <nct_id>NCT04319731</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure</brief_title>
  <official_title>A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effect of purified (acellular) amniotic fluid as a
      treatment for SARS CoV-2 (COVID19)-associated respiratory failure. Past use of human amniotic
      products (i.e., membrane and fluid) is FDA-approved for tissue injury and has been used to
      reduce inflammation and fibrosis in patients with a variety of medical conditions. The
      investigators hypothesize that using nebulized and/or intravenous purified (acellular)
      amniotic fluid will reduce both inflammation in patients hospitalized for in SARS CoV-2
      (COVID19)-associated respiratory failure, potentially leading to a decrease in respiratory
      support.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Anticipated">March 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator Free Days</measure>
    <time_frame>Measured from hospital admission day 60 after admission.</time_frame>
    <description>Days alive and off mechanical ventilation at day 60. Measured only among patients who receive invasive mechanical ventilation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of supplemental oxygen use</measure>
    <time_frame>Measured from hospital admission to day 60.</time_frame>
    <description>Duration from hospital admission until cessation of supplemental oxygen use. Measured only among patients who do not receive invasive mechanical ventilation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>Measured at day 60 or at hospital discharge, whichever comes first.</time_frame>
    <description>Survival at day 60 or hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic inflammation</measure>
    <time_frame>Measured at day 5 post enrollment.</time_frame>
    <description>Systemic inflammation at 5 days measured by serum IL-6.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>SARS CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment groups:
1. Acute care and ICU - 10mL intravenous amniotic fluid every 24 hours for 5 days (6mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human Amniotic Fluid</intervention_name>
    <description>Administration of amniotic fluid in SARS-CoV-2 positive patients</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age â‰¥18

          -  2. Hospitalized and symptomatic (cough, fevers, SOB, or sputum production)

          -  3. SARS CoV-2 laboratory positive obtained within 14 days of enrollment

        Exclusion Criteria:

          -  1. None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Selzman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Selzman, MD</last_name>
    <phone>(801) 581-5311</phone>
    <email>craig.selzman@hsc.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joseph Tonna, MD</last_name>
    <phone>(801) 581-5311</phone>
    <email>joseph.tonna@hsc.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Utah Health</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Selzman, MD</last_name>
      <phone>801-581-5311</phone>
      <email>craig.selzman@hsc.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 22, 2020</study_first_submitted>
  <study_first_submitted_qc>March 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Craig Selzman</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Amniotic fluid</keyword>
  <keyword>Respiratory failure</keyword>
  <keyword>Critical illness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

